TEL AVIV, Israel and JACKSONVILLE, FL - (July 18, 2023) ActiGraft PRO is now commercially available in the US and eligible for reimbursement from Medicare and Medicare Advantage via NCD 270.3 and G-0465 & G-0460 codes. Medicare and Medicare Advantage plans will now reimburse $1,726 per application for up to 20 applications. This eligibility applies to diabetic foot ulcer (DFU) treatment.

ActiGraft is an autologous product by RedDress. Applied directly to the wound surface, the ActiGraft PRO blood clot is created at the patient's bedside in under 5 minutes by mixing fresh whole blood with our proprietary coagulation powder. ActiGraft PRO contains whole blood cells including white cells, red cells, plasma, platelets, and fibrin, in the optimal concentration required in the wound healing process. Once applied, ActiGraft PRO facilitates the healing cascade and serves as a protective covering.

To learn more about ActiGraft PRO and its eligibility for reimbursement in the US, click here.